StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)

Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –

Alnylam Pharmaceuticals enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Alnylam Pharmaceuticals's enterprise value was $18.07B on Nov 11, 2026, against $56.74B a year earlier. Over the last 5 years it ranged from $12.98B to $56.87B, with a median of $24.89B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$18.07B-63.6%
2025Dec 31, 2025$49.68B+80.4%
2024Dec 31, 2024$27.55B+27.4%
2023Dec 29, 2023$21.62B-19.9%
2022Dec 30, 2022$26.99B+49.9%
2021Dec 31, 2021$18.01B+35.2%
2020Dec 31, 2020$13.32B+20.0%
2019Dec 31, 2019$11.10B+80.8%
2018Dec 31, 2018$6.14B-43.1%
2017Dec 29, 2017$10.79B+329.5%
2016Dec 30, 2016$2.51B-64.1%
2015Dec 31, 2015$7.00B+2.2%
2014Dec 31, 2014$6.85B+76.8%
2013Dec 31, 2013$3.87B+432.2%
2012Dec 31, 2012$727.58M+316.0%
2011Dec 30, 2011$174.89M-5.1%
2010Dec 31, 2010$184.33M–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?